Subscribe
Halawi / Shutterstock.com
20 August 2025NewsEuropeMarisa Woutersen

Astellas win strengthens blockbuster drug's European position

The Japanese pharma company has defended a key patent for a treatment that achieved record 2024 sales of over $6 billion—but a patent cliff looms.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Astellas defends Xtandi patent as court rejects generics’ appeal
23 July 2025   Court of Appeal backs Astellas in UK patent fight over prostate cancer drug | Generics’ challenge fails as judges warn on expert evidence and hindsight bias | Court urges caution when instructing expert witnesses in obviousness cases.
Europe
Astellas defends blockbuster cancer treatment patent
8 October 2024   A UK court upholds the patent for Astellas Pharma's life-extending prostate cancer treatment | Judgment dismisses attempts by Accord Healthcare, Sandoz, and Teva to invalidate the patent | Parallel litigation in Germany and Netherlands ongoing.
Americas
Pfizer sues Chinese pharma firm over prostate cancer drug
6 August 2024   Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.


Editor's picks

Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025

Editor's picks

Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Europe
Astellas defends Xtandi patent as court rejects generics’ appeal
23 July 2025   Court of Appeal backs Astellas in UK patent fight over prostate cancer drug | Generics’ challenge fails as judges warn on expert evidence and hindsight bias | Court urges caution when instructing expert witnesses in obviousness cases.
Europe
Astellas defends blockbuster cancer treatment patent
8 October 2024   A UK court upholds the patent for Astellas Pharma's life-extending prostate cancer treatment | Judgment dismisses attempts by Accord Healthcare, Sandoz, and Teva to invalidate the patent | Parallel litigation in Germany and Netherlands ongoing.
Americas
Pfizer sues Chinese pharma firm over prostate cancer drug
6 August 2024   Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.

More on this story

Europe
Astellas defends Xtandi patent as court rejects generics’ appeal
23 July 2025   Court of Appeal backs Astellas in UK patent fight over prostate cancer drug | Generics’ challenge fails as judges warn on expert evidence and hindsight bias | Court urges caution when instructing expert witnesses in obviousness cases.
Europe
Astellas defends blockbuster cancer treatment patent
8 October 2024   A UK court upholds the patent for Astellas Pharma's life-extending prostate cancer treatment | Judgment dismisses attempts by Accord Healthcare, Sandoz, and Teva to invalidate the patent | Parallel litigation in Germany and Netherlands ongoing.
Americas
Pfizer sues Chinese pharma firm over prostate cancer drug
6 August 2024   Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.

More features

Roche sues over blockbuster cancer drug as key patent protection expires
Apple Watch revives key medtech feature after import ban
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
Judge overturns Amgen’s $50m damages loss
Weil adds two more litigators from larger rival
Why the PTAB’s new expedited filing dates for AIA petitions is positive
Ninth Circuit revives trade secrets claims in DNA-sequencing spat
Latham steps into dispute over $6bn treatment, replacing Kirkland